These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37125917)

  • 1. The
    Wickramage I; Peng Z; Chakraborty S; Harmanus C; Kuijper EJ; Alrabaa S; Smits WK; Sun X
    Microbiol Spectr; 2023 Jun; 11(3):e0377722. PubMed ID: 37125917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-Genome Sequencing Reveals the High Nosocomial Transmission and Antimicrobial Resistance of Clostridioides difficile in a Single Center in China, a Four-Year Retrospective Study.
    Wen X; Shen C; Xia J; Zhong LL; Wu Z; Ahmed MAEE; Long N; Ma F; Zhang G; Wu W; Luo J; Xia Y; Dai M; Zhang L; Liao K; Feng S; Chen C; Chen Y; Luo W; Tian GB
    Microbiol Spectr; 2022 Feb; 10(1):e0132221. PubMed ID: 35019676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reference Susceptibility Testing and Genomic Surveillance of Clostridioides difficile, United States, 2012-17.
    Gargis AS; Karlsson M; Paulick AL; Anderson KF; Adamczyk M; Vlachos N; Kent AG; McAllister G; McKay SL; Halpin AL; Albrecht V; Campbell D; Korhonen LC; Elkins CA; Rasheed JK; Guh AY; McDonald LC; Lutgring JD;
    Clin Infect Dis; 2023 Mar; 76(5):890-896. PubMed ID: 36208202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response.
    Eubank TA; Dureja C; Garey KW; Hurdle JG; Gonzales-Luna AJ
    Clin Infect Dis; 2024 Jul; 79(1):15-21. PubMed ID: 38382090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of
    Bassères E; Eubank TA; Begum K; Alam MJ; Jo J; Le TM; Lancaster CK; Gonzales-Luna AJ; Garey KW
    Antimicrob Agents Chemother; 2024 Mar; 68(3):e0162123. PubMed ID: 38364016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribotypes and antimicrobial susceptibility profiles of clinical Clostridioides difficile isolates: A multicenter, laboratory-based surveillance in Taiwan, 2019-2021.
    Tsai CS; Lu PL; Lu MC; Hsieh TC; Chen WT; Wang JT; Ko WC
    J Microbiol Immunol Infect; 2024 Apr; 57(2):320-327. PubMed ID: 38135646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.
    Costa DVS; Pham NVS; Hays RA; Bolick DT; Goldbeck SM; Poulter MD; Hoang SC; Shin JH; Wu M; Warren CA
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0048922. PubMed ID: 35861541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of Clinical Clostridioides difficile Isolates With Decreased Susceptibility to Vancomycin.
    Darkoh C; Keita K; Odo C; Oyaro M; Brown EL; Arias CA; Hanson BM; DuPont HL
    Clin Infect Dis; 2022 Jan; 74(1):120-126. PubMed ID: 35016207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
    Nelson RL; Suda KJ; Evans CT
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models.
    Tashiro S; Taguchi K; Enoki Y; Matsumoto K
    Clin Microbiol Infect; 2023 May; 29(5):616-622. PubMed ID: 36574949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of eravacycline against common ribotypes of Clostridioides difficile.
    Bassères E; Begum K; Lancaster C; Gonzales-Luna AJ; Carlson TJ; Miranda J; Rashid T; Alam MJ; Eyre DW; Wilcox MH; Garey KW
    J Antimicrob Chemother; 2020 Oct; 75(10):2879-2884. PubMed ID: 32719870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clostridioides (Clostridium) difficile in adults with diarrhoea in Vietnam.
    Khun PA; Phi LD; Bui HTT; Collins DA; Riley TV
    Anaerobe; 2023 Jun; 81():102741. PubMed ID: 37244476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic determinants of resistance to antimicrobial therapeutics are rare in publicly available Clostridioides difficile genome sequences.
    Kolte B; Nübel U
    J Antimicrob Chemother; 2024 Jun; 79(6):1320-1328. PubMed ID: 38598696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A US-based national surveillance study for the susceptibility and epidemiology of
    Snydman DR; McDermott LA; Thorpe CM; Goldstein EJC; Schuetz AN; Johnson S; Gerding DN; Gluck L; Bourdas D; Carroll KC; Lancaster CK; Garey KW; Wang Q; Walk ST; Duperchy E
    Antimicrob Agents Chemother; 2023 Oct; 67(10):e0034923. PubMed ID: 37728368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring novel microbial metabolites and drugs for inhibiting
    Abouelkhair AA; Seleem MN
    mSphere; 2024 Jul; 9(7):e0027324. PubMed ID: 38940508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study.
    Freeman J; Vernon J; Pilling S; Morris K; Nicolson S; Shearman S; Clark E; Palacios-Fabrega JA; Wilcox M;
    Eur J Clin Microbiol Infect Dis; 2020 Jan; 39(1):169-177. PubMed ID: 31811507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility of Clostridioides difficile isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian Clostridioides difficile (CAN-DIFF) surveillance study from 2013 to 2017.
    Karlowsky JA; Adam HJ; Baxter MR; Dutka CW; Nichol KA; Laing NM; Golding GR; Zhanel GG
    J Antimicrob Chemother; 2020 Jul; 75(7):1824-1832. PubMed ID: 32294172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Houston, We Have a Problem: Reports of Clostridioides difficile Isolates With Reduced Vancomycin Susceptibility.
    Greentree DH; Rice LB; Donskey CJ
    Clin Infect Dis; 2022 Oct; 75(9):1661-1664. PubMed ID: 35653393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015-18.
    Putsathit P; Hong S; George N; Hemphill C; Huntington PG; Korman TM; Kotsanas D; Lahra M; McDougall R; McGlinchey A; Moore CV; Nimmo GR; Prendergast L; Robson J; Waring L; Wehrhahn MC; Weldhagen GF; Wilson RM; Riley TV; Knight DR
    J Antimicrob Chemother; 2021 Jun; 76(7):1815-1821. PubMed ID: 33895826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.